Abstract:Esophageal squamous cell carcinoma (ESCC) is a prevalent cancer with high morbidity and mortality worldwide. Radiotherapy is one major curative treatment modality for ESCC. Herein, our study aimed to investigate whether CAFs (cancer-associated fibroblasts), a main component of tumor microenvironment, were involved in mediating the development of radioresistance and further explored the mechanisms underlying CAFs-mediated radioresistance in ESCC. By primary culture, two pairs of CAFs and matched NFs (normal fibroblasts) had been successfully isolated from tumor tissues of ESCC patients and matched normal esophageal epithelial tissues, respectively. The secretion of chemokines by CAFs and matched NFs was determined by the human chemokine antibody array. The concentrations of chemokine in culture medium of CAFs, matched NFs and ESCC cells were determined by Elisa assay. The effect of CAFs-secreted chemokines on radioresistance was investigated in vitro by clonogenic survival assay, detection of DNA double-strand breaks (DSBs) and by flow cytometry analysis on cell apoptosis. By establishment of xenograft tumor models in BALB/c nude mice, the effect of CAFs on radioresistance was investigated in vivo. CAFs conferred ESCC cells KYSE-30 and KYSE-150 significant radioresistance by promoting clonogenic survival and inhibiting DSBs and cell apoptosis following radiation in comparison with their matched NFs. Mechanism studies revealed that human chemokine CXCL1 (The chemokine [C-X-C motif] ligand 1) was secreted by CAFs at a significantly higher level compared with matched NFs and ESCC cells. Inhibition of CXCL1 expression in CAFs by the human specific antibody against CXCL1 significantly reversed CAFs-mediated radioresistance by enhancing radiation-induced DSBs, and inhibiting DNA damage repair response and the activation of anti-apoptotic Mek/Erk signaling pathway. The use of CXCL1 antibody also significantly reversed CAFs-mediated radioresistance in xenograft tumor models. Further studies demonstrated that CAFs-secreted CXCL1 suppressed the expression of antioxidant enzyme SOD1 (superoxide dismutases), leading to accelerated ROS (Reactive Oxygen Species) accumulation which activated DNA damage repair response and mediated the radioresistance. Moreover, the crosstalk of CAFs and ESCC cells induced CXCL1 expression in an autocrine/paracrine signaling loop by which the radioresistance was further enhanced. Our study for the first time discovered CAFs-secreted CXCL1 as an attractive target to reverse the radioresistance of ESCC.

The enhancement of radiosensitivity in human esophageal squamous cell carcinoma cells by zoledronic acid and its potential mechanism

Zoledronic Acid Augments the Radiosensitivity of Cancer Cells Through Perturbing S- and M-phase Cyclins and P21cip1 Expression.

Xrcc3 is A Promising Target to Improve the Radiotherapy Effect of Esophageal Squamous Cell Carcinoma

Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma.

Effects and Underlying Mechanisms of Homologous Recombina-Tion-associated Protein XRCC3 on Esophageal Squamous-Cell Carci-Noma Radiotherapy Response

PD-1 Inhibitor Enhanced Radiosensitivity by Reactivating T Cells and Inducing G2/M Phase Arrest in Esophageal Squamous Cell Carcinoma

LncRNA DGCR5 Silencing Enhances the Radio-Sensitivity of Human Esophageal Squamous Cell Carcinoma via Negatively Regulating the Warburg Effect

Effect of sinomenine hydrochloride on radiosensitivity of esophageal squamous cell carcinoma cells.

Anlotinib Combined with Chemoradiotherapy Exhibits Significant Therapeutic Efficacy in Esophageal Squamous Cell Carcinoma

Targeting Valosin-Containing Protein Enhances the Efficacy of Radiation Therapy in Esophageal Squamous Cell Carcinoma.

Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma

CAFs-Secreted CXCL1 Mediated Radioresistance by Regulating DNA Damage Response in an ROS-Dependent Manner in Esophageal Squamous Cell Carcinoma

Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions

Combine radiotherapy and immunotherapy in esophageal squamous cell carcinoma

CAF-secreted CXCL1 conferred radioresistance by regulating DNA damage response in a ROS-dependent manner in esophageal squamous cell carcinoma

Safety and Feasibility of Radiotherapy Plus Camrelizumab for Locally Advanced Esophageal Squamous Cell Carcinoma

EphA5 Silencing Increases the Radiosensitivity of ESCC Cells Through ATM-Dependent Pathway

Ultrasound-Stimulated Microbubbles Inhibit Aggressive Phenotypes and Promotes Radiosensitivity of esophageal squamous cell carcinoma

Delineate Genomic and Epigenomic Changes in Esophageal Squamous Cell Carcinoma Following Radiation Therapy

PD0166285 sensitizes esophageal squamous cell carcinoma to radiotherapy by dual inhibition of WEE1 and PKMYT1

Ribosomal S6 protein kinase 4 promotes radioresistance in esophageal squamous cell carcinoma